Oculis Holding Past Earnings Performance
Past criteria checks 0/6
Oculis Holding's earnings have been declining at an average annual rate of -37.2%, while the Pharmaceuticals industry saw earnings growing at 9.3% annually. Revenues have been declining at an average rate of 2.7% per year.
Key information
-37.2%
Earnings growth rate
24.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 21.5% |
| Revenue growth rate | -2.7% |
| Return on equity | -59.2% |
| Net Margin | -7,674.2% |
| Next Earnings Update | 08 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Oculis Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -67 | 20 | 0 |
| 31 Mar 24 | 1 | -59 | 18 | 0 |
| 31 Dec 23 | 1 | -89 | 17 | 0 |
| 30 Sep 23 | 1 | -85 | 18 | 0 |
| 30 Jun 23 | 1 | -78 | 16 | 0 |
| 31 Mar 23 | 1 | -75 | 13 | 0 |
| 31 Dec 22 | 1 | -39 | 11 | 0 |
| 30 Sep 22 | 1 | -35 | 8 | 0 |
| 31 Dec 21 | 1 | -19 | 5 | 0 |
| 31 Dec 20 | 1 | -15 | 4 | 0 |
Quality Earnings: OCS is currently unprofitable.
Growing Profit Margin: OCS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCS is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.
Accelerating Growth: Unable to compare OCS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.4%).
Return on Equity
High ROE: OCS has a negative Return on Equity (-59.24%), as it is currently unprofitable.